9 ± 0.4 years of age; 63.5 ± 4.0 kg), were recruited from competitive swimming clubs in Ontario, Canada to participate in the current study. All participants had at least #PCI-34051 chemical structure randurls[1|1|,|CHEM1|]# 3 years experience in competitive swimming and had achieved regional, provincial and/or national level qualifications. Informed consent was obtained from all participants and their parents. The study procedures were approved by the Health Canada Natural Health Products Directorate and the Brock University Research Ethics Board. Experimental design The current study used a randomized, double-blinded, placebo controlled, cross-over design. All participants

performed four swimming trials under four treatment conditions determined by the amount of, and time over which, Na-CIT dihydrate [(HCOONa)2 * 2(H2O)] was ingested. Specifically, all participants randomly performed the following 4 trials; two experimental: 1) acute (ACU), 2) chronic (CHR), and 2 placebo: 3) acute placebo (PLC-A), and 4) chronic placebo (PLC-C). Each

Na-CIT supplementation trial was separated by at least a six-day washout period. The order of trials was randomly assigned to each participant by a computerized random number generator. The study was conducted during the mid-season training period (March-April) in a 4-week window without competition in order to minimize fluctuations in training volume and tapering effects. During this period, the swimmers trained 14–19 hours/week including 12–16 hours of swimming click here sets and 0–5 Branched chain aminotransferase hours

of weight training. Their training consisted of: a) seven to nine variant-load swimming sessions per week of medium to high-intensity, and b) two to three constant-load weight training sessions per week. The participants were instructed to maintain their individual training programs. Additionally, they were advised to refrain from any high-intensity exercise and to continue their nutritional habits between the four swimming trials. Supplementation protocol Sodium Citrate (Victoria Compounding Pharmacy) was delivered in solution with 500 mL of flavored water (Crystal Light Pink Lemonade); the placebo consisted of similarly flavored water (Crystal Light Pink Lemonade). Ten adult volunteers tested multiple flavors (Strawberry-Banana-Orange, Lemon-Lime, and Pink Lemonade), with and without Na-CIT, to find an optimal masking flavor in an effort to maintain blinded supplementation. Volunteers were blinded to which samples contained Na-CIT. After sampling and revealing which drinks contained Na-CIT, the volunteers chose the Pink Lemonade as the best masking flavor for the supplementation protocols. According to McNaughton [4], the optimal ACU dose of Na-CIT was 0.5 g kg-1; therefore, the ACU trial involved taking 0.5 g kg-1 of Na-CIT in solution with 500 mL of flavored water consumed 120 min prior to performance according to the timing protocol described by Oopik et al. [13]. The CHR dose involved taking 0.